Role of MRI and FIGO Staging in Evaluation of Fibroids - A Pictorial Review.

Shrivastava A, Jindal G, Kalpdev A, Sethi S, Rastogi E, Aggarwal C, Amin KT, Sethi A

Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor.

Marmarelis ME, Sun L, Aggarwal C

Toxicities and Deaths From Intercurrent Disease Following Contemporary Postoperative Radiotherapy in Resected Non-Small-Cell Lung Cancer.

Kim KN, Heintz J, Yegya-Raman N, Cohen R, Kegelman T, Cengel K, Marmarelis M, Sun L, Langer C, Aggarwal C, Singh A, Singhal S, Kucharczuk J, Robinson K, Feigenberg S

Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice.

Aggarwal C, Ramasamy V, Garg A, Shukla R, Khanna N

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Aggarwal C, Saba NF, Algazi A, Sukari A, Seiwert TY, Haigentz M, Porosnicu M, Bonomi M, Boyer J, Esser MT, Cheng LI, Agrawal S, Jennings EC, Durham NM, Fraser K, Lissa D, Gong M, Ceaicovscaia N, GascĂł HernĂĄndez A, Kumar R

Sinococuline, a bioactive compound of Cocculus hirsutus has potent anti-dengue activity.

Shukla R, Ahuja R, Beesetti H, Garg A, Aggarwal C, Chaturvedi S, Nayyar K, Arora U, Lal AA, Khanna N

Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer.

Yegya-Raman N, Kegelman TP, Ho Lee S, Kallan MJ, Kim KN, Natarajan J, Deek MP, Zou W, O'Reilly SE, Zhang Z, Levin W, Cengel K, Kao G, Cohen RB, Sun LL, Langer CJ, Aggarwal C, Singh AP, O'Quinn R, Ky B, Apte A, Deasy J, Xiao Y, Berman AT, Jabbour SK, Feigenberg SJ

Next-generation ctDNA-driven clinical trials in precision immuno-oncology.

Aggarwal C, Leighl NB

Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis.

Yeung V, Sackstein P, Grant NN, Krochmal R, Gandhi N, Aggarwal C, Halmos B, Reuss JE, Liu SV, Kim C

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.

Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A

Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?

Mountzios G, Aggarwal C

Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?

Aggarwal C, Gyawali B

Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations.

Kurzrock R, Aggarwal C, Weipert C, Kiedrowski L, Riess J, Lenz HJ, Gandara D

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

Vega DM, Nishimura KK, Zariffa N, Thompson JC, Hoering A, Cilento V, Rosenthal A, Anagnostou V, Baden J, Beaver JA, Chaudhuri AA, Chudova D, Fine AD, Fiore J, Hodge R, Hodgson D, Hunkapiller N, Klass DM, Kobie J, PeĂąa C, Pennello G, Peterman N, Philip R, Quinn KJ, Raben D, Rosner GL, Sausen M, Tezcan A, Xia Q, Yi J, Young AG, Stewart MD, Carpenter EL, Aggarwal C, Allen J

Clinical and Epidemiological Profile of Elderly Hodgkin's Lymphoma in India.

Sharma M, Goyal P, Ranjan R, Maheshwari U, Bhurani D, Aggarwal C, Koyyala VPB, Jain P, Agrawal N, Ahmed R